1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Spinocerebellar Ataxias - Pipeline Review, H2 2013

Spinocerebellar Ataxias - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 37 pages

Spinocerebellar Ataxias - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Spinocerebellar Ataxias - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Spinocerebellar Ataxias, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinocerebellar Ataxias. Spinocerebellar Ataxias - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Spinocerebellar Ataxias.
- A review of the Spinocerebellar Ataxias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Spinocerebellar Ataxias pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Spinocerebellar Ataxias.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Spinocerebellar Ataxias pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Spinocerebellar Ataxias - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Spinocerebellar Ataxias Overview 6
Therapeutics Development 7
Pipeline Products for Spinocerebellar Ataxias - Overview 7
Pipeline Products for Spinocerebellar Ataxias - Comparative Analysis 8
Spinocerebellar Ataxias - Therapeutics under Development by Companies 9
Spinocerebellar Ataxias - Therapeutics under Investigation by Universities/Institutes 10
Spinocerebellar Ataxias - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Spinocerebellar Ataxias - Products under Development by Companies 14
Spinocerebellar Ataxias - Products under Investigation by Universities/Institutes 15
Spinocerebellar Ataxias - Companies Involved in Therapeutics Development 16
Kissei Pharmaceutical Co., Ltd. 16
Vybion, Inc. 17
Spinocerebellar Ataxias - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Assessment by Therapeutic Class 26
Drug Profiles 28
KPS-0373 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
lithium carbonate - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
lithium carbonate - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
shAtx3 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
INT-41 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Spinocerebellar Ataxias - Recent Pipeline Updates 34
Spinocerebellar Ataxias - Dormant Projects 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37



List of Tables

Number of Products under Development for Spinocerebellar Ataxias, H2 2013 7
Number of Products under Development for Spinocerebellar Ataxias - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Spinocerebellar Ataxias - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2013 16
Spinocerebellar Ataxias - Pipeline by Vybion, Inc., H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Stage and Target, H2 2013 20
Number of Products by Stage and Mechanism of Action, H2 2013 21
Number of Products by Stage and Route of Administration, H2 2013 23
Number of Products by Stage and Molecule Type, H2 2013 25
Number of Products by Stage and Therapeutic Class, H2 2013 27
Spinocerebellar Ataxias Therapeutics - Recent Pipeline Updates, H2 2013 34
Spinocerebellar Ataxias - Dormant Projects, H2 2013 35



List of Figures

Number of Products under Development for Spinocerebellar Ataxias, H2 2013 7
Number of Products under Development for Spinocerebellar Ataxias - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Early Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Top 10 Target, H2 2013 19
Number of Products by Stage and Top 10 Target, H2 2013 20
Number of Products by Top 10 Route of Administration, H2 2013 22
Number of Products by Stage and Top 10 Route of Administration, H2 2013 23
Number of Products by Top 10 Molecule Type, H2 2013 24
Number of Products by Stage and Top 10 Molecule Type, H2 2013 25
Number of Products by Top 10 Therapeutic Class, H2 2013 26
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 27



Companies Mentioned

Kissei Pharmaceutical Co., Ltd.
Vybion, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Amyloid Precursor Protein (APP) - Pipeline Review, H2 2016

Amyloid Precursor Protein (APP) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Amyloid Precursor Protein (APP) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Amyloid Precursor Protein (APP) - Pipeline Review, H2 2016’, provides in depth analysis on Amyloid Precurso ...

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline ...

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 o ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.